Preclinical discovery and clinical development of encorafenib for the treatment of melanoma

Authors:

Abstract
Nearly 50% of patients with metastatic melanoma harbor a BRAFV600-mutation, which can be targeted with the use of BRAF and MEK inhibitors, either in the front-line or treatment-refractory setting. ...

This publication has 39 references indexed in Scilit: